Cancer Research Meeting Calendar  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on June 23, 2009
[Cancer Research, 10.1158/0008-5472.CAN-09-0390]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow All Versions of this Article:
0008-5472.CAN-09-0390v1
69/14/5726    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Wallace, A. E.
Right arrow Articles by Jabbour, H. N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallace, A. E.
Right arrow Articles by Jabbour, H. N.

Cell, Tumor, and Stem Cell Biology

Prostaglandin F2{alpha}-F-Prostanoid Receptor Signaling Promotes Neutrophil Chemotaxis via Chemokine (C-X-C Motif) Ligand 1 in Endometrial Adenocarcinoma

Alison E. Wallace 1, Kurt J. Sales 1, Roberto D. Catalano 1, Richard A. Anderson 1, 2, Alistair R.W. Williams 3, Martin R. Wilson 1, Jurgen Schwarze 4, Hongwei Wang 4, Adriano G. Rossi 4, and Henry N. Jabbour 1*

1Medical Research Council Human Reproductive Sciences Unit, Departments of 2Reproductive and Developmental Sciences and 3Pathology, and 4Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, United Kingdom

* To whom correspondence should be addressed. E-mail: H.Jabbour{at}hrsu.mrc.ac.uk.


   Abstract

The prostaglandin F2{alpha} (PGF2{alpha}) receptor (FP) is elevated in endometrial adenocarcinoma. This study found that PGF2{alpha} signaling via FP regulates expression of chemokine (C-X-C motif) ligand 1 (CXCL1) in endometrial adenocarcinoma cells. Expression of CXCL1 and its receptor, CXCR2, are elevated in cancer tissue compared with normal endometrium and localized to glandular epithelium, endothelium, and stroma. Treatment of Ishikawa cells stably transfected with the FP receptor (FPS cells) with 100 nmol/L PGF2{alpha} increased CXCL1 promoter activity, mRNA, and protein expression, and these effects were abolished by cotreatment of cells with FP antagonist or chemical inhibitors of Gq, epidermal growth factor receptor, and extracellular signal-regulated kinase. Similarly, CXCL1 was elevated in response to 100 nmol/L PGF2{alpha} in endometrial adenocarcinoma explant tissue. CXCL1 is a potent neutrophil chemoattractant. The expression of CXCR2 colocalized to neutrophils in endometrial adenocarcinoma and increased neutrophils were present in endometrial adenocarcinoma compared with normal endometrium. Conditioned media from PGF2{alpha}-treated FPS cells stimulated neutrophil chemotaxis, which could be abolished by CXCL1 protein immunoneutralization of the conditioned media or antagonism of CXCR2. Finally, xenograft tumors in nude mice arising from inoculation with FPS cells showed increased neutrophil infiltration compared with tumors arising from wild-type cells or following treatment of mice bearing FPS tumors with CXCL1-neutralizing antibody. In conclusion, our results show a novel PGF2{alpha}-FP pathway that may regulate the inflammatory microenvironment in endometrial adenocarcinoma via neutrophil chemotaxis. [Cancer Res 2009;69(14):OF1–8]

Key Words: Prostaglandin F2{alpha}, endometrial cancer, neutrophil, CXCL1, CXCR2







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.